# US 2025/0093367 A1 · Quantification of low amounts of antibody side-products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0093367 A1
- Document ID: US20250093367A1
- Status: Published application
- Kind: A1
- Application number: 18/672,669
- Filed: 2024-05-23
- Published: 2025-03-20
- Earliest claimed: 2021-11-25
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Laurent LARIVIERE; Tilman SCHLOTHAUER; Christian SPICK; Adrian ZWICK
- Web page: https://patentgrep.com/patent/US20250093367A1

## CPC

- G01N 33/54373: {involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings}
- G01N 33/6857: {Antibody fragments}
- C07K 16/18: against material from animals or humans
- C07K 16/2881: {against CD71}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- G01N 21/59: Transmissivity (G01N21/25 takes precedence)
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/6854: {Immunoglobulins}
- C07K 2317/31: multispecific
- C07K 2317/35: Valency
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 21/553: {and using surface plasmons (fluorescence excitation G01N21/648; enhanced Raman G01N21/658)}
- G01N 2021/5903: {using surface plasmon resonance [SPR], e.g. extraordinary optical transmission [EOT]}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The current invention is directed to a method for determining homodimeric avid-binding side-products of a bispecific antibody in a sample comprising the correctly assemble heterodimeric affine-binding bispecific antibody and the mis-assembled homodimeric avid-binding side-product of the bispecific antibody using surface plasmon resonance, wherein the correctly assembled heterodimeric affine-binding bispecific antibody comprises one or more binding site for a first antigen and one or more binding sites for a second antigen, wherein the mis-assembled homodimeric avid-binding side-product of the bispecific antibody comprises two or more binding sites to the first antigen but at least more than the correctly assembled bispecific antibody, wherein the correctly assembled bispecific antibody is a heterodimer and the mis-assembled bispecific antibody is a homodimer, wherein the presence of the homodimeric avid-binding side-product is determined if residual binding, i.e. an increased SPR signal, can be determined in the dissolution phase of the SPR analysis.

## Claims

### Claim 1

A method for determining avid-binding side-products of a bispecific antibody in a sample comprising correctly assembled bispecific antibody and one or more avid-binding side-product of the bispecific antibody using surface plasmon resonance,
wherein the correctly assembled bispecific antibody comprises one or more binding site for a first antigen and one or more binding sites for a second antigen,
wherein the avid-binding side-product of the bispecific antibody comprises two or more binding sites to the first antigen and more binding sites to the first antigen than the correctly assembled bispecific antibody,
the method comprising the following steps:
i) applying a loading solution comprising the correctly assembled bispecific antibody to an SPR surface on which the first antigen has been immobilized with at least 1000 RU to generate an SPR signal, applying thereafter a dissolution solution not comprising a compound binding to the first antigen to the SPR chip and recording the decay of the SPR signal,
ii) applying a sample solution suspected to comprise an avid-binding side-product of the bispecific antibody to an SPR surface on which the first antigen has been immobilized with at least 1000 RU to generate an SPR signal, applying thereafter a dissolution solution not comprising a compound binding to the first antigen to the SPR chip and recording the decay of the SPR signal,
iii) determining the avid-binding side-product of the bispecific antibody if the decay of the SPR signal determined in step ii) is slower than the decay of the SPR signal determined in step i).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the first antigen is immobilized with at least 2000 RU.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the first antigen is immobilized with at least 2000 RU and at most 8000 RU.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the applying of the loading solution and/or the sample is for at least 300 seconds at a flow rate of 5 μL/min to 50 μL/min.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the applying of the loading solution and/or the sample is for at least 400 seconds at a flow rate of 5 μL/min to 50 μL/min.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the applying of the dissolution solution is for at least 600 seconds at a flow rate of 5 μL/min to 50 μL/min.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the applying of the dissolution solution is for at least 1200 seconds at a flow rate of 5 μL/min to 50 μL/min.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the applying of the loading solution and the sample is under the same conditions.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the applying of the dissolution solution in steps i) and ii) is under the same conditions.

### Claim 10 (depends on 4)

The method according to claim 4, wherein the flow rate is 15 μL/min to 35 μL/min.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the determining in step iii) is with the SPR signal determined at a time point at least 400 sec. after the start of the application of the dissolution solution, and wherein the SPR signal obtained with the loading solution at the start of the application of the dissolution solution in step i) and ii) is made identical.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the determining in step iii) is with the SPR signal determined at a time point at least 1200 sec. after the start of the application of the dissolution solution, and wherein the SPR signal obtained with the loading solution at the start of the application of the dissolution solution in step i) and ii) is made identical.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the antibody is
i) a bispecific antibody in CrossMab format, or
ii) a bispecific antibody in TCB-format, or
iii) a bispecific antibody in 2+1-format.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the method is for determining the presence of an antibody-related homodimeric avid-binding side-product.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the method is for quantifying the presence of an antibody-related homodimeric avid-binding side-product.
